Navigation Links
BioFit Intensive Plus™ Chairs Meet Federal Standard for Continuous Intensive Use
Date:6/12/2009

Plus chair is rated for a 500-lb. capacity, has a 21-inch wide saddle-shaped seat with a waterfall front to ensure even weight distribution, and comes standard with an executive style seat pan control so users can quickly and easily adjust the seat position. The chair's 20-inch wide backrest is molded to provide lumbar and kidney support, and a polished, 5-point, star-shaped aluminum base affords even more support with 3 inch diameter, dual-wheel casters which are load rated at 165 pounds each. Glides are also available instead of casters, and other options include 4 armrest styles.

For more details on the BioFit Intensive Plus chair, visit www.biofit.com or call 1-800-597-0246.

Located in Bowling Green, Ohio, BioFit Engineered Products is an industry-leading designer and manufacturer of LEED-compliant ergonomic seating, GREENGUARD-certified cafeteria and mobile tables, carts and specialty products for high tech, industrial, laboratory, office, healthcare, educational, continuous operations, hospitality, and other environments. BioFit also produces one-of-a-kind seating and table solutions for highly specialized settings and distinct user needs.

Intensive Plus is a trademark of BioFit Engineered Products.

# # #

Read the full story at http://www.prweb.com/releases/2009/06/prweb2521034.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. BioFit Names Rusty Benschoter National Sales & Marketing Manager
2. BioFit 1Y Takes the Plunge to Fill Undersea Seating Role for NOAA
3. BUSM researchers find gram-negative rods in two Philippine neonatal intensive care units
4. Anpath Group, Inc. Distributor Introduces Products at the Japanese Society of Intensive Care Medicine Annual Meeting
5. Blue Cross Blue Shield of Michigan Plans to Offer Customer Groups Ability to Purchase Coverage of Autism Treatment Programs that Provide Intensive Early Intervention
6. Hospital Opens New $19 Million Neonatal Intensive Care Unit
7. More intensive treatment not associated with better outcomes in early bladder cancer
8. Intensive Early Treatment Doesnt Help Bladder Cancer Survival
9. Intensive summer program helps physicians build clinical research careers
10. NICE SUGAR: Intensive insulin therapy risks
11. Dallas To Host Intensive Norvax University Insurance Agent Sales Training and Web Marketing Conference on March 26
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BioFit Intensive Plus™ Chairs Meet Federal Standard for Continuous Intensive Use
(Date:5/30/2015)... Metamora, Michigan (PRWEB) May 30, 2015 ... procedure to lighten or stop periods, without the ... This procedure can reduce or stop menstrual bleeding and ... the uterus (the part that causes the bleeding), with ... million women suffer from heavy menstrual bleeding. Many ...
(Date:5/30/2015)... Diego, CA (PRWEB) May 30, 2015 ... is the lack of local healthcare options available. Often, ... to adequate healthcare. For those in rural areas feeling ... simply without health insurance or tired of paying high ... new E-consults, connecting patients with licensed physicians via the ...
(Date:5/30/2015)... York (PRWEB) May 30, 2015 ... $100 million in punitive and compensatory damages to ... who suffered serious complications following implantation of the ... a verdict rendered on May 28th in Delaware ... in compensatory damages after the jury found that ...
(Date:5/30/2015)... EHO offers a suite of online applications ... the ability to manage their drug-spend for the lowest ... EHO has been able to compete with the big ... survive among the giants of the industry. Since EHO ... ago, it has simplified the way hospices can monitor ...
(Date:5/30/2015)... 30, 2015 Nicole Blodgett, Vice ... Income Associate (DIA) designation to further her expertise ... is designed for insurance advisors, health care professionals, ... knowledge and expertise associated with the risk and ... designation is only the latest accomplishment in Nicole's ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Secura Consultants Expands Disability Insurance Expertise 2
... Michigan Comprehensive Cancer Center have identified a potential new way ... cells in a tumor that fuel its growth and spread. ... by a type of cell derived from bone marrow, called ... marrow to the cancer and create a "niche" for the ...
... Controlling blood pressure is not only a medical challenge, ... required to strictly adhere to a treatment plan that ... the ideas of wellness and health are also powerful ... This is especially true in the African American ...
... 2011 - A recent study by Merikangas and colleagues ... Journal of the American Academy of Child and Adolescent ... that are affected with severely impairing mental disorders ever ... found that approximately one third of adolescents with any ...
... January 18, 2011 Heart disease is the leading cause ... States. But heart disease is more than just one disease; ... heart attack, high blood pressure, diabetes or other causes. In ... accumulation in heart cells. Obesity and high-fat diets are major ...
... the World Health Organisation (WHO), an estimated 322,000 deaths globally ... in many of these cases death could have been avoided ... major burn patients have insufficient skin left to graft on ... literally to be grown from the patient,s own skin cells. ...
... By Kathleen Doheny HealthDay Reporter , ... creams that promise "broad-spectrum" sun protection actually measure up, ... daytime moisturizers claiming to provide broad-spectrum protection from the ... reliable protection from harmful UV-A rays, which can penetrate ...
Cached Medicine News:Health News:U-M researchers find indirect path to attack breast cancer stem cells 2Health News:Storytelling may help control blood pressure in African-Americans 2Health News:Adolescents with severe mental disorders have never received treatment 2Health News:A different path to fat-related heart disease 2Health News:Nanotech medicine 2Health News:Nanotech medicine 3Health News:Nanotech medicine 4Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 2Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 3
(Date:5/29/2015)... and MENLO PARK, Calif. , ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), ... proven cancer therapies in new orphan drug indications, ... Association of Cancer Research (AACR) Advances in Brain ... its lead product candidate VAL-083 (dianhydrogalactitol) ...
(Date:5/29/2015)... 29, 2015 Amgen (NASDAQ: AMGN ... Phase 3, global, randomized, placebo-controlled trials evaluating AMG ... secondary hyperparathyroidism (SHPT) in patients with chronic kidney ... primary endpoint, demonstrating that a greater proportion of ... greater than 30 percent reduction in parathyroid hormone ...
(Date:5/28/2015)... -- Eli Lilly and Company (NYSE: LLY ) announced today ... for up to $1.6 billion aggregate principal amount of certain ... who tendered, and did not validly withdraw, their notes on ... time, on May 27, 2015 (the early tender date), ... to receive the total consideration. The total consideration for each ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... Amgen (Nasdaq: AMGN ) reported revenue unchanged ... $3,812 million for the third quarter of 2009. ... the third quarter of 2010 compared to $1,518 million for ... income was driven by unusually low research and development (R&D) ...
... 25 See video from Novartis: ... New Phase III data indicate that Menveo® (Meningococcal ... demonstrated robust immunogenicity in infants potentially offering protection ... 3. These data were presented during an oral ...
Cached Medicine Technology:Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 2Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 3Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 4Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 5Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 6Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 7Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 8Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 9Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 10Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 11Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 12Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 13Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 14Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 15
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
Medicine Products: